Artificial bone-like substance mimics the way real bone grows at atomic level

Researchers from Chalmers University of Technology, Sweden, have discovered how our bones grow at an atomic level, showing how an unstructured mass orders itself into a perfectly arranged bone structure. The discovery offers new insights, which could yield improved new implants, as well as increasing our knowledge of bone diseases such as osteoporosis.

The bones in our body grow through several stages, with atoms and molecules joining together, and those bigger groupings joining together in turn. One early stage in the growth process is when calcium phosphate molecules crystallize, which means that they transform from an amorphous mass into an ordered structure. Many stages of this transformation were previously a mystery, but now, through a project looking at an imitation of how our bones are built, the researchers have been able to follow this crystallization process at an atomic level. Their results are now published in the scientific journal Nature Communications.

"A wonderful thing with this project is that it demonstrates how applied and fundamental research go hand in hand. Our project was originally focused on the creation of an artificial biomaterial, but the material turned out to be a great tool to study bone building processes. We first imitated nature, by creating an artificial copy. Then, we used that copy to go back and study nature," says Martin Andersson, Professor in Materials Chemistry at Chalmers, and leader of the study.

The researchers were developing a method of creating artificial bone through additive manufacturing, or 3D printing. The resulting structure is built up in the same way, with the same properties, as real bone. Once fully developed, it will enable the formation of naturalistic implants, which could replace the metal and plastic technologies currently in use. As the team began to imitate natural bone tissue functions, they saw that they had created the possibility to study the phenomenon in a setting highly resembling the environment in living tissue.

The team's artificial bone-like substance mimicked the way real bone grows. The smallest structural building blocks in the skeleton are groups of strings consisting of the protein collagen. To mineralize these strings, cells send out spherical particles known as vesicles, which contain calcium phosphate. These vesicles release the calcium phosphate into confined spaces between the collagen strings. There, the calcium phosphate begins to transform from an amorphous mass into an ordered crystaline structure, which creates the bone's characteristic features of remarkable resistance to shocks and bending.
The researchers followed this cycle with the help of electron microscopes and now show in their paper how it happens at the atomic level. Despite the fact that bone crystallization naturally occurs in a biological environment, it is not a biological process. Instead, calcium phosphate's intrinsic physical characteristics define how it crystallizes and builds up, following the laws of thermodynamics. The molecules are drawn to the place where the energy level is lowest, which results in it building itself into a perfectly crystallized structure.

"Within the transmission electron microscope, we could follow the stages of how the material transformed itself into an ordered structure. This enables it to achieve as low an energy level as possible, and therefore a more stable state," says Dr Antiope Lotsari, a researcher in Martin Andersson's group, who conducted the electron microscopy experiments.
The Chalmers researchers are the first to show in high resolution what happens when bones crystallize. The results could influence the way many common bone related illnesses are treated.

"Our results could be significant for the treatment of bone disease such as osteoporosis, which today is a common illness, especially among older women. Osteoporosis is when there is an imbalance between how fast bones break down and are being re-formed, which are natural processes in the body," says Martin Andersson.

Current medicines for osteoporosis, which work through influencing this imbalance, could be improved with this new knowledge. The hope is that with greater precision, we will be able to evaluate the pros and cons of current medicines, as well as experiment with different substances to examine how they hinder or stimulate bone growth.​

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
FDA approves new osteoporosis drug for postmenopausal women with high fracture risk